All In Biotech

Drug Trial Radar · NCT06481098

A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

A Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15275 in Healthy and Obese Subjects

Last checked: Nov 19, 2026Latest source record: May 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

74

Actual

Start

May 28, 2024

Primary completion

May 2, 2025

Study completion May 2, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Study is a Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15275 in Healthy and Obese Subjects.

Conditions

  • Obesity

Interventions

  • HM15275Drug

    HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.

  • Placebo of HM15275Drug

    A sterile, matching solution supplied in pre-filled syringes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Safety and TolerabilityTime frame: Up to Day 29
  2. Part B: Safety and TolerabilityTime frame: Up to Day 57

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ProSciento, Inc.

    Chula Vista, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.